Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis by Liang-Kun Guo, Yi Su, Yu-Ya-Nan Zhang, Hao Yu, Zhe Lu, Wen-Qiang Li, Yong-Feng Yang, Xiao Xiao, Hao Yan, Tian-Lan Lu, Jun Li, Yun-Dan Liao, Zhe-Wei Kang, Li-Fang Wang, Yue Li, Ming Li, Bing Liu, Hai-Liang Huang, Lu-Xian Lv, Yin Yao, Yun-Long Tan, Gerome Breen, Ian Everall, Hong-Xing Wang, Zhuo Huang, Dai Zhang, Wei-Hua Yue

“…The discovery cohort was recruited from the CAPOC trial (n = 2307) involved 6 weeks of treatment and equally randomized the participants to the Olanzapine, Risperidone, Quetiapine, Aripiprazole, Ziprasidone, and Haloperidol/Perphenazine (subsequently equally assigned to one or the other) groups. …”
Get full text

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial by Minhan Dai, Yulu Wu, Yiguo Tang, Weihua Yue, Hao Yan, Yamin Zhang, Liwen Tan, Wei Deng, Qi Chen, Guigang Yang, Tianlan Lu, Lifang Wang, Fude Yang, Fuquan Zhang, Jianli Yang, Keqing Li, Luxian Lv, Qingrong Tan, Hongyan Zhang, Xin Ma, Lingjiang Li, Chuanyue Wang, Xiaohong Ma, Dai Zhang, Hao Yu, Liansheng Zhao, Hongyan Ren, Yingcheng Wang, Xun Hu, Guangya Zhang, Xiaodong Du, Qiang Wang, Tao Li

“…There was no differential contribution of high- and low trajectories to different drugs (χ2 = 12.52, P = 0.051); olanzapine and risperidone, which had a larger proportion in the >50% reduction at week 6, performed better than aripiprazole, quetiapine, ziprasidone and perphenazine. Conclusions The trajectory analysis of treatment response to schizophrenia revealed two distinct trajectories. …”
Get full text